Gilead Sciences has agreed to acquire Arcellx for $115 per share in cash plus a non-transferable contingent value right worth up to an additional $5 per share tied to anito-cel sales, implying an equity value of about $7.8 billion at closing. The companies expect the deal to close in the second quarter of 2026, subject to customary closing conditions, and Gilead currently owns about 11.5% of Arcellx.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260222105602) on February 23, 2026, and is solely responsible for the information contained therein.